Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to announce its partnership with Lupin, a global pharmaceutical company, to enhance drug discovery processes across multiple therapeutic areas. Leveraging advanced artificial intelligence technologies, Partex will empower Lupin's Global Business Development and Licensing (BD&L) team with actionable insights to identify promising assets for the inhalation/respiration and central nervous system (CNS) fields.

As part of this collaboration, Partex will employ its cutting-edge AI algorithms to sift through vast amounts of data and evaluate various aspects of potential assets, including drug class, mechanism of action, indications, route of administration, formulation, dosages, innovation, indication expansion potential, competition, market opportunity, and clinical probability of success. This comprehensive approach ensures that Lupin receives highly relevant and meticulously assessed insights to guide its strategic decision-making process.

Additionally, Partex will explore new indications through hypothesis validation, utilizing the screening capabilities of its affiliate, Assay.Works. This strategic integration of resources further solidifies the partnership's commitment to innovation and breakthrough discoveries in the pharmaceutical landscape.

"We are excited to partner with Lupin to revolutionize drug discovery through the power of artificial intelligence," said Gunjan Bhardwaj, CEO at Partex. "Our advanced AI-driven platform will enable Lupin to identify and evaluate promising assets with unparalleled efficiency and precision, ultimately accelerating the development of innovative therapies for patients worldwide."

This partnership marks a significant milestone in the pharmaceutical industry, highlighting the transformative potential of AI-driven solutions in streamlining drug discovery processes and bringing life-changing treatments to market faster.

For media inquiries and further information, please contact:
Partex
Nidhi Duhan
Business Operations Manager
info@partex.io

About Partex:

With the power of AI at its core, the Partex Group delivers faster, lower-cost healthcare innovations, validated by wet-lab and real-world evidence. Our pioneering digital platform enables smarter decision-making throughout the entire value chain.

Partex’s pioneering digital life-science platform leverages the largest knowledge graph in the industry to impact the full pharma and healthcare value chain. Our agile teams use a flexible and scalable data exchange and insight generation approach to enable maximally informed decision-making. To further solidify the translation of AI-generated predictions into tangible outcomes, Partex's Contract Research Organization (CRO), Assay.Works, can conduct wet lab validation for selected indications upon client’s request. This critical step underscores the commitment to delivering safe and efficacious therapies to patients.

We deliver value to patients, clients, and investors through faster, lower-cost healthcare innovations with an increased probability of success.

With a global presence that extends from Asia-Pacific to the Americas, with offices currently in India, Germany, Switzerland, and the USA, Partex’s vision is to transform the Life Science Industry by solving the inefficiency problem in drug discovery & development using Big Data & Artificial Intelligence.

Partex group companies: https://www.partex.io/ https://www.innoplexus.com/ https://www.cureteq.com/ www.amrit.ai https://www.assay.works/ https://perpetualblock.io/

For more information, visit https://www.partex.io/ and follow us on LinkedIn, Twitter and Instagram.